Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMVT NASDAQ:LNTH NASDAQ:RAPP NASDAQ:SYRE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$32.67+4.9%$28.20$14.32▼$36.28$6.71B0.761.66 million shs1.34 million shsLNTHLantheus$102.82+2.6%$86.93$47.25▼$103.89$6.69B-0.03962,293 shs826,240 shsRAPPRapport Therapeutics$37.49+1.3%$35.39$10.51▼$42.27$1.79B0.97333,575 shs203,975 shsSYRESpyre Therapeutics$78.48+6.7%$65.34$13.93▼$79.54$6.82B3.05946,551 shs1.12 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant+0.74%-6.76%+14.86%+16.58%+101.75%LNTHLantheus+4.10%+1.17%+17.25%+31.37%+29.04%RAPPRapport Therapeutics+6.02%-6.35%+9.18%+24.79%+202.29%SYRESpyre Therapeutics+6.30%+1.39%+5.91%+81.13%+343.69%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMVTImmunovant$32.67+4.9%$28.20$14.32▼$36.28$6.71B0.761.66 million shs1.34 million shsLNTHLantheus$102.82+2.6%$86.93$47.25▼$103.89$6.69B-0.03962,293 shs826,240 shsRAPPRapport Therapeutics$37.49+1.3%$35.39$10.51▼$42.27$1.79B0.97333,575 shs203,975 shsSYRESpyre Therapeutics$78.48+6.7%$65.34$13.93▼$79.54$6.82B3.05946,551 shs1.12 million shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMVTImmunovant+0.74%-6.76%+14.86%+16.58%+101.75%LNTHLantheus+4.10%+1.17%+17.25%+31.37%+29.04%RAPPRapport Therapeutics+6.02%-6.35%+9.18%+24.79%+202.29%SYRESpyre Therapeutics+6.30%+1.39%+5.91%+81.13%+343.69%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMVTImmunovant 2.45Hold$37.3314.27% UpsideLNTHLantheus 2.73Moderate Buy$101.86-0.94% DownsideRAPPRapport Therapeutics 2.90Moderate Buy$58.8356.93% UpsideSYRESpyre Therapeutics 3.00Buy$91.3316.38% UpsideCurrent Analyst Ratings BreakdownLatest RAPP, IMVT, LNTH, and SYRE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026SYRESpyre Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$102.00 ➝ $115.006/2/2026RAPPRapport Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/26/2026LNTHLantheus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/26/2026IMVTImmunovant GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$44.00 ➝ $62.005/22/2026IMVTImmunovant Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$23.00 ➝ $30.005/21/2026IMVTImmunovant CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/21/2026IMVTImmunovant HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$35.00 ➝ $40.005/21/2026IMVTImmunovant Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$32.00 ➝ $43.005/21/2026RAPPRapport Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $65.005/18/2026RAPPRapport Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$44.00 ➝ $56.00(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMVTImmunovantN/AN/AN/AN/A$4.19 per shareN/ALNTHLantheus$1.54B4.34$6.82 per share15.08$16.43 per share6.26RAPPRapport TherapeuticsN/AN/AN/AN/A$10.17 per shareN/ASYRESpyre Therapeutics$890K7,657.53N/AN/A$7.21 per share10.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMVTImmunovant-$505.61M-$2.78N/AN/AN/AN/A-65.66%-59.88%8/10/2026 (Estimated)LNTHLantheus$233.56M$4.1524.7819.15N/A18.05%29.32%15.00%8/5/2026 (Estimated)RAPPRapport Therapeutics-$111.48M-$2.60N/AN/AN/AN/A-24.78%-23.44%8/6/2026 (Estimated)SYRESpyre Therapeutics-$155.20M-$2.08N/AN/AN/AN/A-42.88%-27.76%8/4/2026 (Estimated)Latest RAPP, IMVT, LNTH, and SYRE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2026IMVTImmunovant-$0.60-$0.73-$0.13-$0.73N/AN/A5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/7/2026Q1 2026RAPPRapport Therapeutics-$0.56-$0.42+$0.14-$0.42$7.50 million$20.00 million5/5/2026Q1 2026SYRESpyre Therapeutics-$0.66-$0.74-$0.08-$0.74$70.87 millionN/A3/10/2026Q4 2025RAPPRapport Therapeutics-$0.65-$0.72-$0.07-$0.72N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthIMVTImmunovantN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ASYRESpyre TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMVTImmunovantN/A9.099.09LNTHLantheus0.472.832.64RAPPRapport TherapeuticsN/A27.0827.08SYRESpyre TherapeuticsN/A8.978.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMVTImmunovant47.08%LNTHLantheus99.06%RAPPRapport TherapeuticsN/ASYRESpyre Therapeutics80.39%Insider OwnershipCompanyInsider OwnershipIMVTImmunovant1.80%LNTHLantheus1.70%RAPPRapport Therapeutics12.48%SYRESpyre Therapeutics15.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMVTImmunovant120205.31 million201.61 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionableRAPPRapport TherapeuticsN/A47.83 million41.86 millionN/ASYRESpyre Therapeutics7386.84 million73.22 millionOptionableRAPP, IMVT, LNTH, and SYRE HeadlinesRecent News About These CompaniesSYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock UpJune 4 at 12:01 PM | zacks.comScott Burrows Sells 7,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockJune 4 at 7:45 AM | insidertrades.comSpyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpAJune 3 at 8:00 AM | globenewswire.comWhy Spyre Therapeutics (SYRE) Is Down 6.1% After Broadening Its SPY003 Paragon License TermsJune 3 at 1:01 AM | finance.yahoo.comSeven Grand Managers LLC Buys Shares of 100,000 Spyre Therapeutics, Inc. $SYREMay 28, 2026 | marketbeat.comSpyre Therapeutics to Participate in Upcoming June Investor ConferencesMay 26, 2026 | globenewswire.comPSP Research LLC Takes Position in Spyre Therapeutics, Inc. $SYREMay 20, 2026 | marketbeat.comLifeSci Capital Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)May 18, 2026 | theglobeandmail.comUBS Group AG Has $22.30 Million Stake in Spyre Therapeutics, Inc. $SYREMay 12, 2026 | marketbeat.comVanguard Group Inc. Has $132.19 Million Stock Position in Spyre Therapeutics, Inc. $SYREMay 12, 2026 | marketbeat.comState of New Jersey Common Pension Fund D Invests $547,000 in Spyre Therapeutics, Inc. $SYREMay 12, 2026 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year High - Time to Buy?May 11, 2026 | marketbeat.comF m Investments LLC Acquires 48,825 Shares of Spyre Therapeutics, Inc. $SYREMay 10, 2026 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Director Sells $5,952,000.00 in StockMay 9, 2026 | insidertrades.comMichael Thomas Henderson Sells 80,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) StockMay 8, 2026 | marketbeat.comSpyre Therapeutics (SYRE) Projected to Post Quarterly Earnings on ThursdayMay 7, 2026 | marketbeat.comSpyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $97.00 at CitigroupMay 6, 2026 | marketbeat.comSpyre Therapeutics’ Exclusive Forum Clauses Shift Legal Leverage, Raise Venue and Litigation Cost Concerns for StockholdersMay 6, 2026 | tipranks.comSpyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5, 2026 | globenewswire.comSpyre Therapeutics (NASDAQ:SYRE) CFO Sells $892,125.00 in StockMay 2, 2026 | insidertrades.comSpyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million RaiseMay 1, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026Apple Talks Just Changed Everything for IntelBy Sam Quirke | May 6, 2026IonQ Just Posted a Breakout Quarter—But 1 Problem RemainsBy Nathan Reiff | May 7, 2026Quantum Stocks Just Got a Lifeline—Who Benefits Most?By Nathan Reiff | May 26, 2026What IBM's $10-Billion Quantum Project Means For Smaller PlayersBy Nathan Reiff | June 3, 2026RAPP, IMVT, LNTH, and SYRE Company DescriptionsImmunovant NASDAQ:IMVT$32.67 +1.52 (+4.88%) Closing price 04:00 PM EasternExtended Trading$32.64 -0.04 (-0.11%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.Lantheus NASDAQ:LNTH$102.82 +2.57 (+2.56%) Closing price 04:00 PM EasternExtended Trading$102.80 -0.01 (-0.01%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.Rapport Therapeutics NASDAQ:RAPP$37.49 +0.49 (+1.32%) Closing price 04:00 PM EasternExtended Trading$37.50 +0.01 (+0.03%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Spyre Therapeutics NASDAQ:SYRE$78.48 +4.96 (+6.75%) Closing price 04:00 PM EasternExtended Trading$77.75 -0.73 (-0.93%) As of 05:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand Medtronic Bottoms, Healthy Rebound Ahead From Runway to Riches: Victoria's Secret's New Look Coke's $10B India IPO Plan Pops the Top on Hidden Value Dell's AI Toll Bridge Is Paved with Record Margins The Blue Origin Explosion Is a Setback for Amazon, Not a Dealbreaker GitLab’s Price Recovery Gains Traction—Time to Get On Board? Ulta's Q1 Report Primes It for a Beauty of a Rebound Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
